Chemistry:Olomorasib

From HandWiki

Olomorasib (LY3537982) is an experimental anticancer drug which acts as an inhibitor of the G12C mutant form of Kirsten rat sarcoma virus (KRAS), an oncogene commonly present in several forms of cancer. It is in early stage clinical trials against lung and colorectal cancers and advanced solid tumors.[1][2][3][4][5]

See also

References

  1. ↑ "Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor.". Cancer Research 81 (13_Supplement): 1259. July 2021. doi:10.1158/1538-7445.AM2021-1259. 
  2. ↑ "Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer". Journal of Cancer Immunology 6 (2): 62–69. 2024. doi:10.33696/cancerimmunol.6.086. PMID 39175850. 
  3. ↑ "Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study". Journal of Clinical Oncology 42 (3_suppl): 94. 2024. doi:10.1200/JCO.2024.42.3_suppl.94. 
  4. ↑ "Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC". Journal of Clinical Oncology 42 (16_suppl): 8510. 2024. doi:10.1200/JCO.2024.42.16_suppl.8510. 
  5. ↑ "Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors". Journal of Clinical Oncology 42 (16_suppl): 3007. 2024. doi:10.1200/JCO.2024.42.16_suppl.3007. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Olomorasib&oldid=4028441"